Clinical Trial Update: A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in Parkinson's disease patients with moderate to severe dyskinesia conducted by Contera Pharma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• Investigational product (Contera Pharma)

Snippet

Sponsor: Contera Pharma | Conditions: Dyskinesias | Phase 2 | Status: COMPLETED